


Appl. No. 10/717,559
 Amendment dated: April 23, 2007
 Reply to OA of: March 22, 2007

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:



1(currently amended). A pharmaceutical composition capable of enhancing immunity of a mammal comprising a therapeutically effective amount of lanostane having the following chemical formula (I) as an active ingredient, in admixture of a pharmaceutically acceptable carrier or diluent for the active ingredient:




(I)

wherein R_1 is either H or CH_3 ; R_2 is $OCOCH_3$, $[[C=O]] \equiv \underline{O}$ or OH; R_3 is H or OH; R_4 is $-C(=CH_2)-C(CH_3)_2R_a$, wherein R_a is H or OH, or $-CH=C(CH_3)-R_b$, wherein R_b is CH_3 or CH_2OH ; R_5 is H or OH; and R_6 is CH_3 or CH_2OH .

2(original). The pharmaceutical composition according to claim 1, wherein the lanostane (I) is



Appl. No. 10/717,559
Amendment dated: April 23, 2007
Reply to OA of: March 22, 2007



3(original). The pharmaceutical composition according to claim 1 comprising 0.1-60% of the lanostane (I) by weight of the composition.

4(original). The pharmaceutical composition according to claim 1, which is orally administered.

5(original). The pharmaceutical composition according to claim 1, wherein said mammal is a human.

6(original). A Poria extract capable of enhancing immunity of a mammal comprising 5-60% of a lanostane (I) as defined in claim 1 by weight of the extract, and being substantially devoid of secolanostane.

7(original). The Poria extract according to claim 6, which is prepared by a method comprising the following steps:

- a) extracting metabolites, fermentation products or sclerotium of Poria cocos (Schw) Wolf by water, methanol, ethanol, or a mixed solvent thereof;
- b) concentrating the resulting liquid extract from step a);
- c) introducing the resulting concentrated substance from step b) into a silica gel column;

Appl. No. 10/717,559
Amendment dated: April 23, 2007
Reply to OA of: March 22, 2007

d) eluting the silica gel column with an eluent having a low polarity, and collecting the resulting eluate;

e) concentrating the eluate to form a concentrated eluate.

8(original). The *Poria* extract according to claim 7, wherein the concentrated eluate from step e) has a chromatographic value, R_f , not less than 0.1 in accordance with a thin layer chromatography, which is developed by a mixed solvent of dichloromethane : methanol = 96:4 and is detected by an ultraviolet lamp and iodine vapor.

9(original). The *Poria* extract according to claim 7, wherein the extraction in step a) is carried out by using 95% ethanol.





10(original). The *Poria* extract according to claim 7, wherein the concentrated substance resulted from step b) is further extracted with a two-phase solvent containing methanol and n-hexane in a volumetric ratio of 1:1, a methanol layer is separated from the two-phase solvent extraction mixture, and the methanol layer is concentrated to form a concentrate, which is used as a feed to the silica gel column in step c).

11(original). The *Poria* extract according to claim 7, wherein the low polarity eluent is a mixed solvent containing dichloromethane and methanol in a volumetric ratio of 96.5:3.5.

12(original). The *Poria* extract according to claim 6 comprising 10-20% of the lanostane (I).

13(original). The *Poria* extract according to claim 6, wherein the lanostane (I) is

Appl. No. 10/717,559
Amendment dated: April 23, 2007
Reply to OA of: March 22, 2007



or

Claims 14-23(canceled).